381 related articles for article (PubMed ID: 19441934)
1. Novel camptothecin derivatives as topoisomerase I inhibitors.
Basili S; Moro S
Expert Opin Ther Pat; 2009 May; 19(5):555-74. PubMed ID: 19441934
[TBL] [Abstract][Full Text] [Related]
2. The clinical pharmacology of topoisomerase I inhibitors.
Abang AM
Semin Hematol; 1998 Jul; 35(3 Suppl 4):13-21. PubMed ID: 9779877
[TBL] [Abstract][Full Text] [Related]
3. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids.
Fox BM; Xiao X; Antony S; Kohlhagen G; Pommier Y; Staker BL; Stewart L; Cushman M
J Med Chem; 2003 Jul; 46(15):3275-82. PubMed ID: 12852757
[TBL] [Abstract][Full Text] [Related]
5. Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity.
Sukhanova A; Grokhovsky S; Zhuze A; Devy J; Pluot M; Oleinikov V; Nabiev I
Anticancer Res; 2003; 23(3B):2609-15. PubMed ID: 12894548
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and antitumor activity of the hexacyclic camptothecin derivatives.
Gao H; Zhang X; Chen Y; Shen H; Pang T; Sun J; Xu C; Ding J; Li C; Lu W
Bioorg Med Chem Lett; 2005 Jul; 15(13):3233-6. PubMed ID: 15913996
[TBL] [Abstract][Full Text] [Related]
7. 20-(S)-camptothecin analogues as DNA topoisomerase I inhibitors: a QSAR study.
Hansch C; Verma RP
ChemMedChem; 2007 Dec; 2(12):1807-13. PubMed ID: 17886246
[TBL] [Abstract][Full Text] [Related]
8. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
Garcia-Carbonero R; Supko JG
Clin Cancer Res; 2002 Mar; 8(3):641-61. PubMed ID: 11895891
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity.
Jaxel C; Kohn KW; Wani MC; Wall ME; Pommier Y
Cancer Res; 1989 Mar; 49(6):1465-9. PubMed ID: 2538227
[TBL] [Abstract][Full Text] [Related]
10. Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs.
Lansiaux A; Léonce S; Kraus-Berthier L; Bal-Mahieu C; Mazinghien R; Didier S; David-Cordonnier MH; Hautefaye P; Lavielle G; Bailly C; Hickman JA; Pierré A
Mol Pharmacol; 2007 Aug; 72(2):311-9. PubMed ID: 17494837
[TBL] [Abstract][Full Text] [Related]
11. [Camptothecin and derivatives: a new class of antitumor agents].
Torck M; Pinkas M
J Pharm Belg; 1996; 51(4):200-7. PubMed ID: 8965250
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase I interactive agents.
Kirstein MN; Turner PK; Stewart CF
Cancer Chemother Biol Response Modif; 2002; 20():99-123. PubMed ID: 12703202
[TBL] [Abstract][Full Text] [Related]
13. Camptothecin: current perspectives.
Thomas CJ; Rahier NJ; Hecht SM
Bioorg Med Chem; 2004 Apr; 12(7):1585-604. PubMed ID: 15028252
[TBL] [Abstract][Full Text] [Related]
14. 14-azacamptothecin: a potent water-soluble topoisomerase I poison.
Cheng K; Rahier NJ; Eisenhauer BM; Gao R; Thomas SJ; Hecht SM
J Am Chem Soc; 2005 Jan; 127(3):838-9. PubMed ID: 15656613
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase I interactive agents.
Stewart CF
Cancer Chemother Biol Response Modif; 2001; 19():85-128. PubMed ID: 11686040
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, topoisomerase I inhibitory activity and in vitro cytotoxicity of camptothecin derivatives bearing five-membered heterocycle containing 10-substituents.
Zhao R; Guan LL; Oreski B; Lown JW
Anticancer Drug Des; 1998 Mar; 13(2):145-57. PubMed ID: 9524556
[TBL] [Abstract][Full Text] [Related]
17. Water soluble inhibitors of topoisomerase I: quaternary salt derivatives of camptothecin.
Lackey K; Sternbach DD; Croom DK; Emerson DL; Evans MG; Leitner PL; Luzzio MJ; McIntyre G; Vuong A; Yates J; Besterman JM
J Med Chem; 1996 Feb; 39(3):713-9. PubMed ID: 8576914
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of new camptothecin analogs with improved antitumor activities.
Niizuma S; Tsukazaki M; Suda H; Murata T; Ohwada J; Ozawa S; Fukuda H; Murasaki C; Kohchi M; Morikami K; Yoshinari K; Endo M; Ura M; Tanimura H; Miyazaki Y; Takasuka T; Kawashima A; Nanba E; Nakano K; Ogawa K; Kobayashi K; Okabe H; Umeda I; Shimma N
Bioorg Med Chem Lett; 2009 Apr; 19(7):2018-21. PubMed ID: 19254843
[TBL] [Abstract][Full Text] [Related]
19. Camptothecin and its analogues: a review on their chemotherapeutic potential.
Sriram D; Yogeeswari P; Thirumurugan R; Bal TR
Nat Prod Res; 2005 Jun; 19(4):393-412. PubMed ID: 15938148
[TBL] [Abstract][Full Text] [Related]
20. [Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance].
Pourquier P; Pommier Y
Bull Cancer; 1998 Dec; Spec No():5-10. PubMed ID: 9932078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
